Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BS01 · 2 trials · 2 indications
Number of subjects with adverse events, changes in hematology/chemistry
| Arm | Type | Description |
|---|---|---|
| BS01 (low dose) | EXPERIMENTAL | - |
| Sham control | SHAM_COMPARATOR | - |
| BS01 (high dose) | EXPERIMENTAL | - |
| Cohort 1 | EXPERIMENTAL | BSO1 Cohort 1 dose |
| Cohort 2 | EXPERIMENTAL | BS01 Cohort 2 dose |
| Cohort 3 | EXPERIMENTAL | BS01 Cohort 3 dose |
| Cohort 4 | EXPERIMENTAL | BS01 Cohort4 dose |
| Cohort 5 | EXPERIMENTAL | BS01 Cohort4 dose |
| Cohort 6 | EXPERIMENTAL | Treat opposite eye |
| Name | Type | Description |
|---|---|---|
| BS01 | BIOLOGICAL | a recombinant adeno-associated virus vector expressing ChronosFP (AAV2-CAGChronosFP) |
| Sham procedure control | OTHER | Sham procedure without needle |
Inclusion Criteria: General Inclusion Criteria 1. Signed informed consent obtained before screening. 2. Men or women between 50 and 85 years of age inclusive at the time of signing the informed consent. Ophthalmic Inclusion Criteria 1. Geographic atrophy with some macula foveal involvement secon...
BS01 is an investigational monoclonal antibody being developed for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) and retinitis pigmentosa. It is administered via intravitreal injection and is currently in Phase 1 clinical trials.
BS01 targets ChronosFP, a molecular target involved in the disease pathways of geographic atrophy and retinitis pigmentosa. By binding to ChronosFP, BS01 aims to modulate the underlying mechanisms of these retinal conditions.
BS01 is being developed by Sight Sciences, Inc., a company traded on the NASDAQ under the ticker symbol SGHT. The company is conducting clinical trials to evaluate the safety and efficacy of BS01 in patients with retinal diseases.
BS01 is in Phase 1 clinical development. It is not yet approved by the FDA and remains investigational. Two Phase 1 trials are currently recruiting patients to assess its safety and efficacy.
BS01 is being studied in two Phase 1 trials. NCT07158775 evaluates BS01 in geographic atrophy secondary to dry AMD with 40 participants, and NCT04278131 evaluates BS01 in retinitis pigmentosa with 20 participants. Both trials are recruiting in the United States.